Psoriatic Arthritis Clinical Features and Epidemiology

Slides:



Advertisements
Similar presentations
Psoriasis Psoriatic Arthritis Cellulitis
Advertisements

Psoriatic Arthritis Emily Chang Morning Report August 14, 2009 August.
What features of inflammatory arthritis aid a rheumatology nurse specialist in diagnosing inflammatory arthritis? G. Gormley 1*, K. Steele 1, D. Gilliland.
Psoriatic Arthritis: Creating a Model for Cost- Effectiveness Analysis GRAPPA meeting San Antonio, TX October 15, 2004 Supported by Schering Participants:
Musculoskeletal Health in Europe Juvenile Idiopathic Arthritis.
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
EPIDEMIOLOGY. General Prevalence of Joint Pain Age-sex adjusted to the 2000 United States (US) standard population. Source: National Health Interview.
Main Points to be Covered
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Psoriatic Arthritis Maggie Davis Hovda Am report 2/16/2010.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
A Guide to Rheumatoid Arthritis for Legislators Rheumatoid Arthritis Policy Resource Center.
A complex and severe disabling disease
World Burden of Cancer Epi 242 Cancer Epidemiology Binh Goldstein, Ph.D. October 7, 2009.
GRAPPA Guidelines for PsA: Considerations
MUSCULOSKELETAL DISEASES National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.
Psoriatic arthritis – definition and classification criteria Philip Helliwell Senior Lecturer in Rheumatology University of Leeds.
Organizational Meeting for the AS-US Working Group Advancing Clinical Research in AS and SpA in the USA Spondylitis Association of America 20 Years of.
Arthritis Facts. Leading Causes of Disability Among U.S. Adults, 1999 Among U.S. Adults, 1999 Arthritis is the leading cause of disability in the United.
Overview of Arthritis Brought to you in collaboration by: 1. Arthritis Foundation Tennessee Chapter 2. Tennessee Department of Health 3. University of.
Non-Radiographic Spondyloarthritis Has Greater Work Instability than Other Spondyloarthritis Subtypes in a National Database Sherry Rohekar 1, Robert D.
Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.
Seronegative Spondyloarthropathies
CASPAR study Philip Helliwell Will Taylor On behalf of the CASPAR study group.
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 2: Diagnostic Classification.
“The African American Prostate Cancer Crisis in Numbers”
Psoriatic Arthritis Workshop OMERACT May 14 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian.
Assessment of enthesitis in psoriatic arthritis
1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.
Show your Best III By: Brad Moatz MSIV. Presentation 42 y.o. male presents with R foot pain and h/o psoriasis.
Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)
OMERACT Workshop Outcome Measures in Psoriatic Arthritis
Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.
Senior Statistician Per-Henrik Zahl, MA MD PhD
High Impact Rheumatology For Primary Care Physicians.
Outcome Measures in PsA Philip Mease MD Seattle, WA.
GRAPPA Guidelines for PsA: Considerations GRAPPA Guidelines Mission Statement: “To develop guidelines, based upon the best scientific evidence, for the.
1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.
GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.
Recommendation 1: Defining & Diagnosing UPIA. Learning Objectives State the definition of Undifferentiated Peripheral Inflammatory Arthritis (UPIA) Describe.
Identifying Early Inflammatory Arthritis
Rheumatoid Arthritis Hayley Evans, CMCBI, King’s College London, UK
Background: In 1964, the American Rheumatism Association listed psoriatic arthritis as a clinical entity. The great variety of clinical manifestations.
Psoriatic arthritis (PsA) Clinical features, Diagnosis & Management
Psoriatic arthritis (PsA) Introduction
FRAX & ITS ASSOCIATIONS IN RHEUMATOID ARTHRITIS
Department of Rheumatology and Connective Tissue Diseases
Musculoskeletal Health in Europe
Ankylosing Spondylitis
Enteropathic Arthropathy
Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA Assessment initiative is.
Vibeke Strand, MD, MACR, Jasvinder A. Singh, MD, MPH 
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Figure 1 Enthesitis versus synovitis
History of the Rochester Epidemiology Project
Figure 3 Simplified EULAR and GRAPPA
Updated 2016 PsA Core Domain Set.
Quantifying the magnitude and the overlap between frailty, multimorbidity and disability in the very old – results from the Newcastle 85+ Study Michael.
What on earth is Spondyloarthritis
Remy A. Pollock, Fatima Abji, Kun Liang, Vinod Chandran, Fawnda J
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.
Dr Sarah Levy Consultant Rheumatologist CUH
Acute Phase Reactants in Patients with UPIA
Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.
common rheumatologic diagnoses
Presentation transcript:

Psoriatic Arthritis Clinical Features and Epidemiology Dafna D. Gladman MD, FRCPC Director, Psoriatic Arthritis Program, University Health Network Centre for Prognosis Studies in the Rheumatic Diseases Toronto Western Hospital Toronto Western Hospital

Psoriatic Arthritis Definition An inflammatory arthritis Associated with psoriasis Usually seronegative for rheumatoid factor

Psoriatic Arthritis Clinical Patterns Distal predominant (Distal inter-phalangeal joints of fingers and toes). Oligo-articular (<5 joints) often in an asymmetric distribution. Poly-articular (5 joints), rheumatoid arthritis-like. Spinal Involvement. ‘Arthritis Mutilans’. Moll & Wright, Seminars Arthritis Rheum 1973;32:181

Psoriatic Arthritis Patterns   Oligoarthritis Distal Arthritis

Psoriatic Arthritis Patterns Polyarticular Pattern

Psoriatic Arthritis Patterns Arthritis Mutilans

Psoriatic Arthritis Patterns Arthritis Mutilans Telescoping

Psoriatic Spondyloarthropathy 

Psoriatic Spondyloarthropathy  

Dactylitis in PsA

Edema in PsA

Heel Lesions in PsA Achilles Tendon Spur Achilles Tendon Insertion Erosion Plantar Spur

Other Radiological Features of PsA Periostitis Tuft resorption

Hidden Psoriasis

PsA Reported Series* *Includes only series with > 100 Patients

Psoriatic arthritis: A distinct entity ? Dutch study found no association between psoriasis and polyarthritis. No association between HLA antigens and seronegative polyarthritis with psoriasis. No radiological features in seronegative polyarthritis with psoriasis. van Romunde LKJ, et al.Rheumatology International 1984;4:55-73. ? fortuitous association Cats A. Cutis 1990;46:323-329.

Psoriatic arthritis Epidemiological Evidence Prevalence of psoriasis in the general population: 0.1-2.8%. Prevalence of psoriasis in arthritis patients: 2.6-7.0%. Prevalence of arthritis in the general population: 2-3%. Prevalence of arthritis in psoriatic patients: 6-42%.

Psoriatic arthritis: A distinct entity ! Previous population studies. Epidemiological studies. Dutch study found DIP joints disease more common in patients with seronegative polyarthritis and psoriasis. A distinct form of arthritis, with different patterns, associated with psoriasis.

A comparison between Psoriatic Arthritis and Rheumatoid Arthritis

Assessment of Tenderness Psoriatic Arthritis Vs. Rheumatoid Arthritis Buskila D, et al. J Rheumatol 1992;19:1115-9.

Psoriatic Arthritis Classification Classified with the Seronegative Spondyloarthropathies: It is usually seronegative for rheumatoid factor. It may be associated with a spondyloarthropathy. It is associated with HLA-B27.

Differentiating PsA from other SpA

Psoriatic Arthritis Prevalence Exact prevalence unknown. Estimated figures vary from 0.1% in Rochester Minnesota to 1.4% in the Faroe Islands. Recent Survey by National Psoriasis Foundation suggests prevalence of 1.4% of general population in the US. Recent study from Toronto suggests a prevalence of 2.5%.

Psoriatic Arthritis Prevalence among people with psoriasis Author (yr) Centre No. Ps. Pts. % PsA Leczinsky (1948) Sweden 534 7 Vilanova (1951) Barcelona 214 25 Little (1975) Toronto 100 32 Scarpa (1984) Napoli 180 34 Stern (1985) Boston 1285 20 Zaneli (1992) Winston-Salem 459 17 Barisic-Drusko (1994) Osijek region 553 10 Salvarani (1995) Regio Emilia 205 36 Shbeeb (2000) Mayo Clinic 1056 6.25 Brockbank (2001) 126 31 NPF (2002) US 4.4 m 23

Psoriatic arthritis Clinical Outcome PsA is much more serious than previously recognized. 20% of patients with PsA develop clinical deformities and damage, resulting in functional disability. 5 deformities were detected in 55% of patients after 10 years of follow-up. Gladman DD et al. Quart J Med 1987;62:127. Torre Alonso et al. Brit J Rheumatol 1991;30:245.

The University of Toronto Psoriatic Arthritis Program Development of Deformities during follow-up Gladman DD. Baillière’s Clinical Rheumatology1994;8:379.

Prognostic Indicators in PsA Clinical Indicators of Progression Progression of damage defined by a change in damage state: State 1 = 0 damaged joints State 2 = 1-4 damaged joints State 3 = 5-9 damaged joints State 4 =  10 damaged joints Analysis by model for rate of transition between damage states. Gladman DD et al. J Rheumatology 1995;22:675.

Prognostic Indicators in PsA Multivariate model for Clinical Indicators of Clinical Progression* *Based on clinical features at presentation Gladman DD et al. J Rheumatology 1995;22:675.

Prognostic Indicators in PsA Multivariate Model for Clinical Damage Gladman DD & Farewell VT. Arthritis Rheum 1995;38:845. Gladman DD, et al. J Rheumatol 1998;25:730.

Prognostic Indicators in Psoriatic Arthritis Final Multivariate Model for Time Varying Clinical Indicators Gladman DD, Farewell VT. J Rheumatol 1999;26:2409

Outcome in Psoriatic arthritis Mortality Studies PsA patients are at an increased risk of death. Overall risk is 1.62 that of Ontario Residents. 1.66 for women, 1.59 for men Causes of Death are similar to general population. Risk of death is related to previously active and severe disease. Wong K, et al. Arthritis Rheum 1997;40:1868-7. Gladman DD, et al. Arthritis Rheum 1998;41:1103-10.

Mortality in Psoriatic Arthritis Primary causes of death in 53 patients

Survival in Psoriatic Arthritis 0.5 0.6 0.7 0.8 0.9 1.0 Survival Probability All patients 5 10 15 20 Time Since Clinic Entry (Years)

Mortality in Psoriatic Arthritis Prognostic Factors: Final Multivariate Model Gladman DD, et al. Arthritis Rheum 1998;41:1103-10.

Remission in Psoriatic Arthritis Summary Remission occurred in 17.6% of our PsA patients. Male gender and less active and severe arthritis at presentation to Clinic were associated with remission. Only 6 (8.7%) of the PsA patients sustained “true remission”, 35 (52%) had subsequent flares. Gladman DD et al. J Rheumatol 2001;28:1045-8.

Psoriatic Arthritis Prognostic Factors Progression of Damage: High effusion count at presentation High joint count at each visit High medication level at presentation Low ESR is “protective” Death: Elevated ESR High prior medication level Radiological Damage Remission Male Gender Low joint count at presentation

Psoriatic Arthritis Not just skin and joints! An inflammatory arthritis associated with psoriasis. More common than previously thought. About one fifth of the patients have a severe debilitating disease, although some patients achieve remission. Earlier studies suggesting that PsA was a mild disease included patients with early disease.

Psoriatic Arthritis Program Dr. Dafna Gladman - Director Cathy Schentag MsC Research Associate CPSRD, TWH Nicole Anderson, BSc Research Assistant CPSRD, TWH Fawnda Pellett, BSC Research Technologist CPSRD, TWH Vern Farewell, PhD Biostatistician MRC, Cambridge, UK Janice Husted, PhD Epidemiologist Waterloo, Ontario Richard Cook, PhD Biostatistician Waterloo, Ontario Research Fellows, Rheumatology Residents, Students,Patients

Psoriatic Arthritis Program - Support Ontario Ministry of Health Medical Research Council / Canadian Institutes of Health Research The Arthritis Society Centre for Prognosis Studies in The Rheumatic Diseases University of Toronto / University Health Network Arthritis Centre of Excellence Krembil Foundation PsA Patients